|
Aug 14
|
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 14
|
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
|
|
Aug 13
|
Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long
|
|
Jul 30
|
Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last?
|
|
Jul 29
|
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
|
|
Jul 29
|
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
|
|
Jul 23
|
7 Biotech Stocks to Keep on Your Clinical Radar
|
|
Jul 23
|
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
|
|
Jun 26
|
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
|
|
Jun 24
|
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
|
|
Jun 14
|
Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 99.89%: Read This Before Placing a Bet
|
|
Jun 13
|
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
|
|
Jun 13
|
FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D
|
|
Jun 12
|
Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why
|
|
Jun 12
|
Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug
|
|
Jun 10
|
Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
|
|
May 31
|
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?
|
|
May 30
|
J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms
|
|
May 29
|
Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty
|
|
May 29
|
Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data
|